Search research articles
Contact Us
Filters
Showing results (81-90 of 174) with videos related to
Page
of 18
Sort By:
Leukemia
|
July 25, 2018
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
Maria Gavriatopoulou, Pellegrino Musto, Jo Caers, et al.
Cells
|
May 13, 2026
MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma
María Labrador, Sara Cozzubbo, Mariangela Porro, et al.
American Journal of Hematology
|
December 23, 2016
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials
Massimo Gentile, Valeria Magarotto, Massimo Offidani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2007
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network
Antonio Palumbo, Patrizia Falco, Paolo Corradini, et al.
Blood
|
May 29, 2008
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo, Sara Bringhen, Anna M Liberati, et al.
Haematologica
|
July 28, 2018
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
Sara Bringhen, Alberto Milan, Claudio Ferri, et al.
Haematologica
|
April 23, 2026
Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma
Michela Cumerlato, Monica Maccagno, María Labrador, et al.
Cancer
|
June 28, 2021
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network
Francesca Gay, Andreas Günther, Massimo Offidani, et al.
Experimental Hematology & Oncology
|
August 10, 2023
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma
Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, et al.
Haematologica
|
April 1, 2021
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Benedetto Bruno, Ralph Wäsch, Monika Engelhardt, et al.
Page
of 18
Search research articles
Search
Showing results (81-90 of 174) with videos related to
Sort By:
Page
of 18
Leukemia
|
July 25, 2018
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
Maria Gavriatopoulou, Pellegrino Musto, Jo Caers, et al.
Cells
|
May 13, 2026
MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma
María Labrador, Sara Cozzubbo, Mariangela Porro, et al.
American Journal of Hematology
|
December 23, 2016
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials
Massimo Gentile, Valeria Magarotto, Massimo Offidani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 6, 2007
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network
Antonio Palumbo, Patrizia Falco, Paolo Corradini, et al.
Blood
|
May 29, 2008
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo, Sara Bringhen, Anna M Liberati, et al.
Haematologica
|
July 28, 2018
Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)
Sara Bringhen, Alberto Milan, Claudio Ferri, et al.
Haematologica
|
April 23, 2026
Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma
Michela Cumerlato, Monica Maccagno, María Labrador, et al.
Cancer
|
June 28, 2021
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network
Francesca Gay, Andreas Günther, Massimo Offidani, et al.
Experimental Hematology & Oncology
|
August 10, 2023
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma
Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, et al.
Haematologica
|
April 1, 2021
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Benedetto Bruno, Ralph Wäsch, Monika Engelhardt, et al.
Page
of 18